Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
4.150
0.00 (0.00%)
May 13, 2026, 4:00 PM EDT - Market closed

Voyager Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
36.4940.3780250.0140.9137.42
Revenue Growth (YoY)
-45.50%-49.53%-68.00%511.16%9.33%-78.14%
Gross Profit
36.4940.3780250.0140.9137.42
Selling, General & Admin
36.1737.5435.9235.8230.9837.25
Research & Development
127.75134.67127.3792.1760.7673.79
Total Operating Expenses
163.92172.22163.29127.9991.74111.03
Operating Income
-127.42-131.84-83.29122.01-50.84-73.62
Interest Income
9.2410.6218.3311.721.79-0.39
Other Non-Operating Income (Expense)
1.671.650.6202.652.81
Total Non-Operating Income (Expense)
10.9112.2718.9511.724.452.42
Pretax Income
-116.52-119.58-64.34133.74-46.39-71.2
Provision for Income Taxes
0.120.140.671.410.02-
Net Income
-116.64-119.72-65132.33-46.41-71.2
Net Income to Common
-116.64-119.72-65132.33-46.41-71.2
Shares Outstanding (Basic)
595958433838
Shares Outstanding (Diluted)
595958453838
Shares Change (YoY)
2.05%2.12%29.39%16.20%1.83%0.86%
EPS (Basic)
-1.98-2.04-1.133.08-1.21-1.89
EPS (Diluted)
-1.97-2.04-1.132.97-1.21-1.89
Shares Outstanding
60.3159.0554.7344.0438.6137.92
Free Cash Flow
-129.94-135.06-18.8374.66-15-55.13
Free Cash Flow Per Share
-2.20-2.29-0.331.68-0.39-1.46
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-349.16%-326.56%-104.11%48.80%-124.28%-196.76%
Profit Margin
-319.61%-296.53%-81.25%52.93%-113.45%-190.29%
FCF Margin
-356.07%-334.53%-23.54%29.86%-36.67%-147.36%
EBITDA
-123.44-127.78-78.56126.46-44.65-68.45
EBITDA Margin
-338.26%-316.50%-98.19%50.58%-109.14%-182.96%
EBIT
-127.42-131.84-83.29122.01-50.84-73.62
EBIT Margin
-349.16%-326.56%-104.11%48.80%-124.28%-196.76%
Effective Tax Rate
-0.10%-0.12%-1.03%1.05%-0.03%0.00%
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q